PMID- 23686401
OWN - NLM
STAT- MEDLINE
DCOM- 20140513
LR  - 20211021
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 21
IP  - 8
DP  - 2013 Aug
TI  - Management of adverse events in patients with hormone receptor-positive breast 
      cancer treated with everolimus: observations from a phase III clinical trial.
PG  - 2341-9
LID - 10.1007/s00520-013-1826-3 [doi]
AB  - Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the 
      treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, 
      subependymal giant cell astrocytoma associated with tuberous sclerosis complex, 
      renal angiomyolipoma and tuberous sclerosis complex, and, in combination with 
      exemestane, for hormone receptor-positive HER2-negative advanced breast cancer 
      after failure of treatment with letrozole or anastrozole. Results from the phase 
      III BOLERO-2 trial demonstrated that everolimus in combination with exemestane 
      provided significant clinical benefit to patients with advanced hormone 
      receptor-positive breast cancer. Although everolimus is generally well tolerated, 
      as with most therapies administered in an advanced cancer setting, drug-related 
      adverse events (AEs) inevitably occur. Most common AEs observed in the everolimus 
      studies include stomatitis, rash, infection, noninfectious pneumonitis, and 
      hyperglycemia. Clinical awareness and early identification of such AEs by 
      oncology nurses are essential to dosing (interruptions, reduction, and treatment 
      discontinuation); quality of life; and, ultimately, patient outcomes. Because 
      everolimus has already been shown to significantly improve clinical efficacy in 
      patients with advanced breast cancer, a proactive approach to the practical 
      management of AEs associated with this mTOR inhibitor as well as other most 
      common AEs observed in this patient population has been reviewed and outlined 
      here.
FAU - Peterson, Mary E
AU  - Peterson ME
AD  - Banner MD Anderson Cancer Center, 2940 Banner Gateway Drive, Suite 400, Gilbert, 
      AZ 85234, USA. Mary.Peterson@bannerhealth.com
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130519
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Androstadienes)
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - NY22HMQ4BX (exemestane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Androstadienes/adverse effects/therapeutic use
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Clinical Trials, Phase III as Topic
MH  - Everolimus
MH  - Exanthema/chemically induced/therapy
MH  - Female
MH  - Humans
MH  - Hyperglycemia/chemically induced/therapy
MH  - Pneumonia/chemically induced/therapy
MH  - Sirolimus/adverse effects/*analogs & derivatives/therapeutic use
MH  - Stomatitis/chemically induced/therapy
MH  - Treatment Outcome
PMC - PMC3699701
EDAT- 2013/05/21 06:00
MHDA- 2014/05/14 06:00
PMCR- 2013/05/19
CRDT- 2013/05/21 06:00
PHST- 2012/09/05 00:00 [received]
PHST- 2013/04/21 00:00 [accepted]
PHST- 2013/05/21 06:00 [entrez]
PHST- 2013/05/21 06:00 [pubmed]
PHST- 2014/05/14 06:00 [medline]
PHST- 2013/05/19 00:00 [pmc-release]
AID - 1826 [pii]
AID - 10.1007/s00520-013-1826-3 [doi]
PST - ppublish
SO  - Support Care Cancer. 2013 Aug;21(8):2341-9. doi: 10.1007/s00520-013-1826-3. Epub 
      2013 May 19.